{
    "xml": "<topic id=\"PHP5301\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/bleomycin\" basename=\"bleomycin\" title=\"BLEOMYCIN\">\n<title>BLEOMYCIN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1008\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antibiotics-cytotoxic/bleomycin\">Bleomycin</xref>\n</p>\n<data name=\"vtmid\">76591000</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_958191424\" title=\"Antineoplastic antibiotics\">Antineoplastic antibiotics</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP59320\" outputclass=\"indicationsAndDose\" rev=\"1.22\" parent=\"/drugs/bleomycin\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Squamous cell carcinoma</p>\n<p outputclass=\"therapeuticIndication\">Metastatic germ cell cancer</p>\n<p outputclass=\"therapeuticIndication\">Non-Hodgkin's lymphoma</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by local infiltration or by intra-arterial infusion or by intramuscular injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59464\" outputclass=\"cautions\" rev=\"1.7\" parent=\"/drugs/bleomycin\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Caution in handling&#8212;irritant to tissues</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59289\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/bleomycin\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (bleomycin).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59146\" outputclass=\"sideEffects\" rev=\"1.24\" parent=\"/drugs/bleomycin\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dermatological toxicity</ph>; <ph outputclass=\"sideEffect\">mucositis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">chills (after drug administration)</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">fever (after drug administration)</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">increased pigmentation particularly affecting the flexures and subcutaneous sclerotic plaques</ph>; <ph outputclass=\"sideEffect\">less bone marrow suppression</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">progressive pulmonary fibrosis (dose-related)</ph>; <ph outputclass=\"sideEffect\">pulmonary toxicity</ph>; <ph outputclass=\"sideEffect\">Raynaud's phenomenon</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hypersensitivity reactions</p>\n<p>Hypersensitivity reactions manifest by chills and fevers commonly occur a few hours after drug administration and may be prevented by simultaneous administration of a corticosteroid, for example hydrocortisone intravenously.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Progressive pulmonary fibrosis</p>\n<p>This is dose-related, occurring more commonly at cumulative doses greater than 300 000&#8239;units and in the elderly. Basal lung crepitations or suspicious chest X-ray changes are an indication to stop therapy with this drug.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Respiratory failure</p>\n<p>Patients who have received extensive treatment with bleomycin (e.g. cumulative dose more than 100 000&#8239;units) may be at risk of developing respiratory failure if a general anaesthetic is given with high inspired oxygen concentrations. Anaesthetists should be warned of this.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59454\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/bleomycin\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59268\" outputclass=\"pregnancy\" parent=\"/drugs/bleomycin\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (teratogenic and carcinogenic in <i>animal</i> studies).</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59472\" outputclass=\"breastFeeding\" parent=\"/drugs/bleomycin\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59193\" outputclass=\"renalImpairment\" parent=\"/drugs/bleomycin\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose by half if serum creatinine 177&#8211;354&#8239;micromol/litre; reduce dose further if serum-creatinine greater than 354&#8239;micromol/ litre.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59708\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.10\" parent=\"/drugs/bleomycin\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>To conform to the European Pharmacopoeia vials previously labelled as containing &#8216;15&#8239;units&#8217; of bleomycin are now labelled as containing 15&#8239;000&#8239;units. The amount of bleomycin in the vial has not changed.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5301-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/bleomycin\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76293\" title=\"Powder for solution for injection\" namespace=\"/drugs/bleomycin/powder-for-solution-for-injection\">Powder for solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78537\" namespace=\"/treatment-summaries/cytotoxic-drugs\" title=\"Cytotoxic drugs\" count=\"2\" rel=\"backlink\">Cytotoxic drugs</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1008\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/antibiotics-cytotoxic/bleomycin\" title=\"Bleomycin\" count=\"1\" rel=\"link\">Bleomycin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76293\" namespace=\"/drugs/bleomycin/powder-for-solution-for-injection\" title=\"Powder for solution for injection\" count=\"1\" rel=\"link\">Powder for solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP5301",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/bleomycin",
    "basename": "bleomycin",
    "title": "BLEOMYCIN",
    "interactants": [
        {
            "id": "bnf_int_1008",
            "label": "Bleomycin"
        }
    ],
    "vtmid": "76591000",
    "drugClassification": [
        "Antineoplastic antibiotics"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Squamous cell carcinoma",
                        "html": "Squamous cell carcinoma"
                    },
                    {
                        "textContent": "Metastatic germ cell cancer",
                        "html": "Metastatic germ cell cancer"
                    },
                    {
                        "textContent": "Non-Hodgkin's lymphoma",
                        "html": "Non-Hodgkin's lymphoma"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or local infiltration or intra-arterial infusion or intramuscular injection or intravenous infusion"
                    ],
                    "textContent": "By intravenous injection or by local infiltration or by intra-arterial infusion or by intramuscular injection or by intravenous infusion",
                    "html": "By intravenous injection or by local infiltration or by intra-arterial infusion or by intramuscular injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Caution in handling&#8212;irritant to tissues",
                "html": "Caution in handling&#8212;irritant to tissues"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (bleomycin).",
                "html": "<p>Appendix 1 (bleomycin).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Dermatological toxicity",
                        "html": "Dermatological toxicity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "mucositis",
                        "html": "mucositis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "chills (after drug administration)",
                        "html": "chills (after drug administration)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fever (after drug administration)",
                        "html": "fever (after drug administration)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "increased pigmentation particularly affecting the flexures and subcutaneous sclerotic plaques",
                        "html": "increased pigmentation particularly affecting the flexures and subcutaneous sclerotic plaques",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "less bone marrow suppression",
                        "html": "less bone marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "progressive pulmonary fibrosis (dose-related)",
                        "html": "progressive pulmonary fibrosis (dose-related)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pulmonary toxicity",
                        "html": "pulmonary toxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "Raynaud's phenomenon",
                        "html": "Raynaud's phenomenon",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Hypersensitivity reactions",
                "textContent": "Hypersensitivity reactions manifest by chills and fevers commonly occur a few hours after drug administration and may be prevented by simultaneous administration of a corticosteroid, for example hydrocortisone intravenously.",
                "html": "<p>Hypersensitivity reactions manifest by chills and fevers commonly occur a few hours after drug administration and may be prevented by simultaneous administration of a corticosteroid, for example hydrocortisone intravenously.</p>"
            },
            {
                "type": "advice",
                "title": "Progressive pulmonary fibrosis",
                "textContent": "This is dose-related, occurring more commonly at cumulative doses greater than 300 000 units and in the elderly. Basal lung crepitations or suspicious chest X-ray changes are an indication to stop therapy with this drug.",
                "html": "<p>This is dose-related, occurring more commonly at cumulative doses greater than 300 000&#8239;units and in the elderly. Basal lung crepitations or suspicious chest X-ray changes are an indication to stop therapy with this drug.</p>"
            },
            {
                "type": "advice",
                "title": "Respiratory failure",
                "textContent": "Patients who have received extensive treatment with bleomycin (e.g. cumulative dose more than 100 000 units) may be at risk of developing respiratory failure if a general anaesthetic is given with high inspired oxygen concentrations. Anaesthetists should be warned of this.",
                "html": "<p>Patients who have received extensive treatment with bleomycin (e.g. cumulative dose more than 100 000&#8239;units) may be at risk of developing respiratory failure if a general anaesthetic is given with high inspired oxygen concentrations. Anaesthetists should be warned of this.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (teratogenic and carcinogenic in animal studies).\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (teratogenic and carcinogenic in <i>animal</i> studies).</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast feeding.",
                "html": "<p>Discontinue breast feeding.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose by half if serum creatinine 177&#8211;354 micromol/litre; reduce dose further if serum-creatinine greater than 354 micromol/ litre.",
                "html": "<p>Reduce dose by half if serum creatinine 177&#8211;354&#8239;micromol/litre; reduce dose further if serum-creatinine greater than 354&#8239;micromol/ litre.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "To conform to the European Pharmacopoeia vials previously labelled as containing &#8216;15 units&#8217; of bleomycin are now labelled as containing 15 000 units. The amount of bleomycin in the vial has not changed.",
                "html": "<p>To conform to the European Pharmacopoeia vials previously labelled as containing &#8216;15&#8239;units&#8217; of bleomycin are now labelled as containing 15&#8239;000&#8239;units. The amount of bleomycin in the vial has not changed.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76293",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78537",
                "label": "Cytotoxic drugs",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1008",
                "label": "Bleomycin",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76293",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}